HOOKIPA Pharma Inc. (HOOK): Price and Financial Metrics
HOOK Price/Volume Stats
| Current price | $0.60 | 52-week high | $2.05 |
| Prev. close | $0.61 | 52-week low | $0.59 |
| Day low | $0.59 | Volume | 312,300 |
| Day high | $0.62 | Avg. volume | 686,920 |
| 50-day MA | $0.73 | Dividend yield | N/A |
| 200-day MA | $0.91 | Market Cap | 50.40M |
HOOK Stock Price Chart Interactive Chart >
HOOKIPA Pharma Inc. (HOOK) Company Bio
HOOKIPA Pharma, Inc. engages in the development of immunotherapeutics, targeting infectious diseases and cancers based on its proprietary its arenavirus platform that is designed to reprogram the body's immune system. Its product include VaxWace, a replication-deficient viral vector; and TheraT, a replication-attenuated viral vector, are designed to induce robust antigen specific CD8+ T cells and pathogen-neutralizing antibodies. The company was founded by Rolf Zinkernagel, Andreas Bergthaler, Lukas Flatz, and Daniel Pinschewer in 2011 and is headquartered in New York, NY.
Latest HOOK News From Around the Web
Below are the latest news stories about HOOKIPA PHARMA INC that investors may wish to consider to help them evaluate HOOK as an investment opportunity.
Hookipa stock surges 46% on license deal with Roche for immunotherapyRoche (OTCQX:RHHBY) (OTCQX:RHHBF) signed a license agreement with Hookipa Pharma (NASDAQ:HOOK) to develop immunotherapy HB-700 for KRAS-mutated cancers and a second undisclosed novel arenaviral immunotherapy. Under the agreement, Hookipa will receive $25M upfront. The Swiss pharma giant will have the option for an anothe... |
HOOK Price Returns
| 1-mo | -12.66% |
| 3-mo | -22.78% |
| 6-mo | -16.82% |
| 1-year | -59.18% |
| 3-year | -93.81% |
| 5-year | N/A |
| YTD | -25.93% |
| 2022 | -65.24% |
| 2021 | -78.99% |
| 2020 | -9.32% |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...